

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Vignina 22313-1450 www.uspto.gov

09/830,559       05/07/2001       Hisaaki Chaki       206704US0PCT       8747         22850       7590       07/16/2003         OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C.       EXAMINER				
OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C. EXAMINER	8747 IN			
	EXAMINER			
1940 DUKE STREET  ALEXANDRIA VA 22214  KAM, CHIH MIN				
ALEXANDRIA, VA 22314				
ART UNIT PAPER NUME	ER			
1653				
DATE MAILED: 07/16/2003				

Please find below and/or attached an Office communication concerning this application or proceeding.

		Att- (	lan 11-			<del></del>
		Applicat		Ap	pplicant(s)	
	Office Action Summary	09/830,5		CH	HAKI ET AL.	
	Onice Action Summary	Examine	r	Ar	t Unit	
		Chih-Min		16		
Period fo	The MAILING DATE of this communicati r Reply	on appears on th	e cover she	eet with the corre	spondence addres	:s
THE N - Exten after: - If the - If NO - Failur - Any re	DRTENED STATUTORY PERIOD FOR I MAILING DATE OF THIS COMMUNICAT is ions of time may be available under the provisions of 37 SIX (6) MONTHS from the mailing date of this communical period for reply specified above is less than thirty (30) day period for reply is specified above, the maximum statutory et or reply within the set or extended period for reply will, be exply received by the Office later than three months after the dispatch term adjustment. See 37 CFR 1.704(b).	FION. CFR 1.136(a). In no evition. rs, a reply within the sta y period will apply and v by statute. cause the apply	vent, however, r tutory minimum vill expire SIX (6	of thirty (30) days will  MONTHS from the manner (35)	led be considered timely. lailing date of this commun	nication.
1)	Responsive to communication(s) filed o	on				
2a) <u></u> □	This action is <b>FINAL</b> . 2b)	☐ This action is	non-final.			
3) 🗌 Disposition	Since this application is in condition for closed in accordance with the practice ton of Claims	allowance excep under <i>Ex parte</i> C	ot for forma <i>Quayle</i> , 193	l matters, prose 5 C.D. 11, 453 (	cution as to the me D.G. 213.	erits is
4)🖂	Claim(s) <u>1-40</u> is/are pending in the appli	ication.				
4	a) Of the above claim(s) is/are wi	ithdrawn from co	nsideration	ı <b>.</b>		
5)[	Claim(s) is/are allowed.					
6)□	Claim(s) is/are rejected.					
7)	Claim(s) is/are objected to.					
8)🖂	Claim(s) <u>1-40</u> are subject to restriction ar	nd/or election red	guirement.			
	on Papers		•			
9)∐ T	he specification is objected to by the Exa	aminer.				
10)∏ T	he drawing(s) filed on is/are: a)	accepted or b)	objected to	by the Examine	r.	
	Applicant may not request that any objection	n to the drawing(s)	be held in a	abeyance. See 37	' CFR 1.85(a).	
11)[] T	he proposed drawing correction filed on _	is: a)∐ a	pproved b)	disapproved disapproved	by the Examiner.	
	If approved, corrected drawings are required	· -	fice action.			
12) <u></u> ⊤	he oath or declaration is objected to by the	he Examiner.				
Priority ur	nder 35 U.S.C. §§ 119 and 120					
13) 🗌 📝	Acknowledgment is made of a claim for fo	oreign priority un	der 35 U.S	.C. § 119(a)-(d)	or (f).	
a) <u>□</u>	] All b) ☐ Some * c) ☐ None of:					
1	. Certified copies of the priority docu	ments have bee	n received.			
2	2. Certified copies of the priority docu	ments have bee	n received	in Application N	o	
	B. Copies of the certified copies of the application from the Internation ee the attached detailed Office action for	e priority docume al Bureau (PCT	ents have b	een received in		е
	knowledgment is made of a claim for dor				a provisional and	ication\
a)	☐ The translation of the foreign languag through the translation of the foreign languag through the translation of the transla	je provisional ap	plication ha	s been received	j,	ication)
Attachment(s		-				
2)  Notice   3)  Informa	of References Cited (PTO-892) of Draftsperson's Patent Drawing Review (PTO-94) tion Disclosure Statement(s) (PTO-1449) Paper No	8) o(s)	4)	e of Informal Patent	-413) Paper No(s) Application (PTO-152)	· ·
Patent and Trad O-326 (Rev.		ce Action Summar		Part o	of Paper No. 10	

## **DETAILED ACTION**

It appears claim 30 has the same scope as claim 36, please cancel one of them.

## Election/Restrictions

- 1. Restriction to one of the following inventions is required under 35 U. S. C. 121:

  The linking claims 1-4, 30, 32-34 and 36 will be examined along with the elected invention of Group I or II.
  - I. Claims 5-8, drawn to a peptide of 10 or 11 residues having the amino acid sequence of SEQ ID NO:1 or 2, classified in class 514, subclass 2.

Should Group I be elected, applicant is required to select one amino acid sequence from claims 5 and 7 identified by a "SEQ ID NO:" with one (1) amino acid residue defined at each position. A peptide with any change of amino acid residue at any one or more positions is considered, absent factual data to the contrary, a distinct peptide.

II. Claims 9-29, 35 and 38-40, drawn to a benzene derivative having various formulas; to an agent for treating an autoimmune disease or a disease related to overexpression of AP-1 comprising the compound; or, to an AP-1 inhibitor comprising the compound, classified in class 514, subclass 252, and class 585, subclass 24.

Should Invention II be elected, applicant is required to select one formula of the benzene derivatives from claims 9, 12, 14, 16, 18, 19, 22, 24, 26 and 28 with each variable defined, e.g., if the formula of claim 9 were elected, applicant is also required to select a specific R<sup>1</sup>, R<sup>3</sup>, R<sup>4</sup>, X<sup>1</sup> and W group for examination. Each benzene derivative with different formula has different

Application/Control Number: 09/830,559

Art Unit: 1653

structure and produces different effect, thus, it is a patentably distinct. This is not species election.

III. Claim 31 and 37, drawn to a method for inhibiting activator protein-1 (AP-1) comprising administering a compound of formula 1 or a benzene derivative of claim 9, classified in class 514, subclass 252, and class 585, subclass 24.

Should Invention III be elected, applicant is required to select a specific R<sup>1</sup>, R<sup>3</sup>, R<sup>4</sup>, X<sup>1</sup> and W group in the formula of benzene derivative. Each benzene derivative has different structure and produces different effect, thus, it is a patentably distinct. This is not species election.

Claims 1-4, 30, 32-34 and 36 link(s) inventions I and II. The restriction requirement between the linked inventions is subject to the nonallowance of the linking claim(s), claims1-4, 30, 32-34 and 36. Upon the allowance of the linking claim(s), the restriction requirement as to the linked inventions shall be withdrawn and any claim(s) depending from or otherwise including all the limitations of the allowable linking claim(s) will be entitled to examination in the instant application. Applicant(s) are advised that if any such claim(s) depending from or including all the limitations of the allowable linking claim(s) is/are presented in a continuation or divisional application, the claims of the continuation or divisional application may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Where a restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. *In re Ziegler*, 44 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01.

Application/Control Number: 09/830,559

Art Unit: 1653

2. The inventions are distinct, each from the other because of the following reasons:

The product of Invention I is distinct from the product of Invention II because they are physically and functionally distinct chemical entities, for example, the peptide can be produced by solid phase peptide synthesis and used as antigen to produce antibody, while the benzene derivative can be made and used in organic synthesis.

The product of Invention I and the method of Invention III are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case, the method of Invention III can be practiced with either the product of Invention II.

The product of Invention II and the method of Invention III are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case, the method of Invention III can be practiced with either the product of Invention I.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by different classification and the recognized divergent subject matter, and because Inventions I-III require different searches but are not co-extensive, examination of these distinct inventions would pose a serious burden on the examiner and therefore restriction for examination purposes as indicated is proper.

Application/Control Number: 09/830,559

Art Unit: 1653

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR

1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the

Page 5

inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the

currently named inventors is no longer an inventor of at least one claim remaining in the

application. Any amendment of inventorship must be accompanied by a petition under 37 CFR

1.48(b) and by the fee required under 37 CFR 1.17(i).

A telephone call was made to Daniel Pereira on July 14, 2003 to request an oral election

to the above restriction requirement, but did not result in an election being made.

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Chih-Min Kam whose telephone number is (703) 308-9437. The

examiner can normally be reached on 8.00-4:30, Mon-Fri.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Christopher Low, Ph. D. can be reached on (703) 308-2923. The fax phone numbers

for the organization where this application or proceeding is assigned are (703) 308-0294 for

regular communications and (703) 308-4227 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding

should be directed to the receptionist whose telephone number is (703) 308-0196.

Chih-Min Kam, Ph. D.

Patent Examiner

July 14, 2003

MK

CHRISTOPHER S. F. LOW SUPERVISORY PATENT EXAMINER

Chris hopher & Show

TECHNOLOGY CENTER 1600